Affected Systems |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
cardiovascular system
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
decreased susceptibility to induced choroidal neovascularization
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal retina vasculature morphology
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
hematopoietic system
|
|
√
|
√
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
myeloid hyperplasia
|
|
|
√
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
thrombocytosis
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased leukocyte cell number
|
|
√
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased granulocyte number
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased basophil cell number
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased eosinophil cell number
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased neutrophil cell number
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased lymphocyte cell number
|
|
√
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased T cell number
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased T-helper 1 cell number
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased monocyte cell number
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal spleen morphology
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal spleen red pulp morphology
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal T cell activation
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
homeostasis/metabolism
|
√
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased circulating glucose level
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal cytokine level
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
immune system
|
|
√
|
√
|
√
|
√
|
|
|
√
|
√
|
√
|
√
|
|
|
|
|
|
|
|
myeloid hyperplasia
|
|
|
√
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased leukocyte cell number
|
|
√
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased granulocyte number
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased basophil cell number
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased eosinophil cell number
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased neutrophil cell number
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased lymphocyte cell number
|
|
√
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased T cell number
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased T-helper 1 cell number
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased monocyte cell number
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal spleen morphology
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal spleen red pulp morphology
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal T cell activation
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal cytokine level
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
enlarged lymph nodes
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increased interferon-gamma secretion
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
rheumatoid arthritis
|
|
|
|
|
|
|
|
|
|
√
|
√
|
|
|
|
|
|
|
|
decreased inflammatory response
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
dermatitis
|
|
|
|
√
|
√
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
integument
|
|
N
|
N
|
√
|
√
|
|
N
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
integument phenotype
|
|
N
|
N
|
N
|
N
|
|
N
|
|
|
|
|
|
|
|
|
|
|
|
dermatitis
|
|
|
|
√
|
√
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
alopecia
|
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal hair follicle dermal papilla morphology
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal dermal layer morphology
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
mixed cellular infiltration to dermis
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal epidermal layer morphology
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
hyperkeratosis
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
orthokeratosis
|
|
|
|
|
√
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
parakeratosis
|
|
|
|
|
√
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
acanthosis
|
|
|
|
|
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
epidermal hyperplasia
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
reddish skin
|
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
scaly skin
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal skin condition
|
|
|
|
|
√
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
psoriasis
|
|
|
|
√
|
√
|
|
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
mortality/aging
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
premature death
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
nervous system
|
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
decreased retina photoreceptor cell number
|
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
retina photoreceptor degeneration
|
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
pigmentation
|
|
|
|
|
N
|
|
|
|
|
|
|
|
|
|
|
|
|
|
pigmentation phenotype
|
|
|
|
|
N
|
|
|
|
|
|
|
|
|
|
|
|
|
|
skeleton
|
|
|
|
|
|
|
|
|
|
√
|
√
|
|
|
|
|
|
|
|
rheumatoid arthritis
|
|
|
|
|
|
|
|
|
|
√
|
√
|
|
|
|
|
|
|
|
vision/eye
|
√
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
decreased susceptibility to induced choroidal neovascularization
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal retina morphology
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal retina vasculature morphology
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
decreased retina photoreceptor cell number
|
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
retina photoreceptor degeneration
|
|
|
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal eye physiology
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|